-
Mashup Score: 5Home Page: ESMO Open - 7 hour(s) ago
Published online: August 29, 2024 Published online: September 5, 2024 Published online: September 5, 2024 Published online: September 9, 2024 Published online: September 4, 2024 International guidelines strongly recommend the use of the homologous recombination deficiency (HRD) test in the selection of first-line maintenance therapy for patients with high-grade serous ovarian cancer. The test has significant prognostic and, importantly, predictive value for the response to PARP inhibitors. However, in
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology - 7 day(s) ago
Burnout in health care professionals (HCPs) results from exposure to psychosocial risks at work. Left unaddressed, burnout can lead to chronic health problems, increased staff turnover, reduced work hours, absenteeism, and early retirement from clinical practice, thus impacting patient care. The European Society for Medical Oncology (ESMO) Resilience Task Force (RTF) was established in December 2019 to support the well-being of oncology HCPs globally. This ESMO RTF position paper aims to provide a set of recommendations to optimise well-being and mitigate burnout in oncology, and to help individuals and institutions maintain the delivery of optimal cancer care.
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet-
To learn more read the recommendations: https://t.co/u8D2sVaHaF
-
-
Mashup Score: 129
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
One of the most important #globaloncology #cancerpolicy studies our group has published. https://t.co/YYGNMhbecW We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit… https://t.co/DkJqL4pibQ https://t.co/ImcIkYahjR
-
-
Mashup Score: 129
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
One of the most important #globaloncology #cancerpolicy studies our group has published. https://t.co/YYGNMhbecW We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit… https://t.co/DkJqL4pibQ https://t.co/ImcIkYahjR
-
-
Mashup Score: 129
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
One of the most important #globaloncology #cancerpolicy studies our group has published. https://t.co/YYGNMhbecW We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit… https://t.co/DkJqL4pibQ https://t.co/ImcIkYahjR
-
-
Mashup Score: 127
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
One of the most important #globaloncology #cancerpolicy studies our group has published. https://t.co/YYGNMhbecW We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit… https://t.co/DkJqL4pibQ https://t.co/ImcIkYahjR
-
-
Mashup Score: 27
Molecular tumor boards (MTBs) are considered beneficial for treatment decision making for patients with cancer with uncommon, rare, or complex mutational profiles. The lack of international MTB guidelines results in significant variation in practices and recommendations. Therefore, periodic follow-up is necessary to assess and govern MTB functioning. The objective of this study was to determine the effectiveness of MTB treatment recommendations for patients with rare and complex mutational profiles as implemented in the MTB of the University Medical Center Groningen (UMCG-MTB) in 2019-2020.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy - ESMO Open https://t.co/ogJmnPtvmv
-
-
Mashup Score: 5Home Page: ESMO Open - 14 day(s) ago
Published online: August 29, 2024 Published online: September 5, 2024 Published online: September 5, 2024 Published online: September 9, 2024 Published online: September 4, 2024 International guidelines strongly recommend the use of the homologous recombination deficiency (HRD) test in the selection of first-line maintenance therapy for patients with high-grade serous ovarian cancer. The test has significant prognostic and, importantly, predictive value for the response to PARP inhibitors. However, in
Source: www.esmoopen.comCategories: General Medicine News, Oncologists1Tweet-
Want to publish your oncology research? Discover what makes ESMO Open unique from the perspective of our Editor-in-Chief, Professor Giuseppe Curigliano. Watch the video now: For more info, visit https://t.co/QkhRU1o6e4 @ESMO_Open https://t.co/C6eDgsDrDb
-
-
Mashup Score: 125
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
One of the most important #globaloncology #cancerpolicy studies our group has published. https://t.co/YYGNMhbecW We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit… https://t.co/DkJqL4pibQ https://t.co/ImcIkYahjR
-
-
Mashup Score: 125
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
One of the most important #globaloncology #cancerpolicy studies our group has published. https://t.co/YYGNMhbecW We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit… https://t.co/DkJqL4pibQ https://t.co/ImcIkYahjR
-
Want to publish your oncology research? Discover what makes ESMO Open unique from the perspective of our Editor-in-Chief, Professor Giuseppe Curigliano. Watch the video now: For more info, visit https://t.co/QkhRU1o6e4 @ESMO_Open https://t.co/C6eDgsDrDb